Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s Why

by · The Cerbat Gem

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $21.23, but opened at $19.74. Nanobiotix shares last traded at $19.73, with a volume of 49,152 shares trading hands.

Wall Street Analyst Weigh In

Several analysts have weighed in on NBTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Wall Street Zen raised Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a report on Tuesday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nanobiotix presently has a consensus rating of “Hold” and an average target price of $11.00.

Read Our Latest Research Report on NBTX

Nanobiotix Price Performance

The firm has a 50 day moving average of $20.35 and a two-hundred day moving average of $11.15.

Hedge Funds Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. purchased a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

Read More